ATE400563T1 - Neue neurokinin-antagonisten zum gebrauch als arzneimittel - Google Patents

Neue neurokinin-antagonisten zum gebrauch als arzneimittel

Info

Publication number
ATE400563T1
ATE400563T1 AT01920055T AT01920055T ATE400563T1 AT E400563 T1 ATE400563 T1 AT E400563T1 AT 01920055 T AT01920055 T AT 01920055T AT 01920055 T AT01920055 T AT 01920055T AT E400563 T1 ATE400563 T1 AT E400563T1
Authority
AT
Austria
Prior art keywords
medicinal products
neurokinin antagonists
new
new neurokinin
antagonists
Prior art date
Application number
AT01920055T
Other languages
English (en)
Inventor
Jeffrey Scott Albert
Peter Bernstein
Cyrus Ohnmacht
Keith Russell
Ashokkumar B Shenvi
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0008727A external-priority patent/GB0008727D0/en
Priority claimed from GB0008728A external-priority patent/GB0008728D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE400563T1 publication Critical patent/ATE400563T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01920055T 2000-04-06 2001-04-05 Neue neurokinin-antagonisten zum gebrauch als arzneimittel ATE400563T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19536500P 2000-04-06 2000-04-06
US19517700P 2000-04-06 2000-04-06
GB0008727A GB0008727D0 (en) 2000-04-11 2000-04-11 Compounds
GB0008728A GB0008728D0 (en) 2000-04-11 2000-04-11 Compounds

Publications (1)

Publication Number Publication Date
ATE400563T1 true ATE400563T1 (de) 2008-07-15

Family

ID=27447827

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01920055T ATE400563T1 (de) 2000-04-06 2001-04-05 Neue neurokinin-antagonisten zum gebrauch als arzneimittel

Country Status (7)

Country Link
EP (1) EP1276729B1 (de)
JP (1) JP2003530388A (de)
AT (1) ATE400563T1 (de)
AU (1) AU2001246999A1 (de)
DE (1) DE60134735D1 (de)
ES (1) ES2307605T3 (de)
WO (1) WO2001077089A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0003476D0 (sv) * 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
SE0201938D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New process
CA2579756C (en) * 2004-06-19 2013-04-30 Human Biomolecular Research Institute Modulators of central nervous system neurotransmitters
WO2006013948A1 (ja) 2004-08-04 2006-02-09 Taisho Pharmaceutical Co., Ltd. トリアゾール誘導体
CN101415691B (zh) 2006-02-03 2011-12-14 大正制药株式会社 三唑衍生物
JP5218737B2 (ja) 2006-02-06 2013-06-26 大正製薬株式会社 スフィンゴシン−1−リン酸結合阻害物質
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
RU2468009C2 (ru) 2007-08-01 2012-11-27 Тайсо Фармасьютикал Ко., Лтд. Ингибитор связывания s1p1
US9782397B2 (en) 2011-07-04 2017-10-10 Irbm Science Park S.P.A. Treatment of corneal neovascularization
CN111918647A (zh) 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂
RU2697414C1 (ru) 2018-05-11 2019-08-14 Общество с ограниченной ответственностью "АЙ БИ ДИ Терапевтикс" Новый антагонист тахикининовых рецепторов и его применение
EP4117673A1 (de) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Behandlung von stammzellenmangel

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9505084D0 (en) * 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
WO2000002859A1 (en) * 1998-07-10 2000-01-20 Astrazeneca Ab N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
GB9922519D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9922521D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9826941D0 (en) * 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression

Also Published As

Publication number Publication date
EP1276729A1 (de) 2003-01-22
EP1276729B1 (de) 2008-07-09
ES2307605T3 (es) 2008-12-01
WO2001077089A1 (en) 2001-10-18
AU2001246999A1 (en) 2001-10-23
DE60134735D1 (de) 2008-08-21
JP2003530388A (ja) 2003-10-14

Similar Documents

Publication Publication Date Title
ATE387199T1 (de) Neue substanzen und verbindungen als protease- inhibitoren
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
SE9904505D0 (sv) Novel compounds
NO20020282L (no) Nytt difenyl-piperidinderivat
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
ATE400563T1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
ATE253359T1 (de) Antithrombotische mittel
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
SE0004827D0 (sv) Therapeutic compounds
ATE293591T1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
SE0102058D0 (sv) New Salts II
ATE286395T1 (de) Antithrombotische mittel
BR0014145A (pt) Compostos de benzimidazol substituìdo por alcóxi, preparações farmacêuticas contendo o mesmo, e métodos de uso do mesmo
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
DE50212538D1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzoäcüfluoren-6-carbonsäurederivate als nmda-antagonisten
ATE334675T1 (de) Arzneimittel enthaltend substituierte 2,5- diaminomethyl-1h-pyrrole

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties